Skip to main content
. 2022 Jan 12;63(1):75–89. doi: 10.1007/s12016-021-08916-8

Table 2.

Nomenclature of monoclonal antibody therapies

Partial name Clinical use or characteristic
Beginning of name Chosen by manufacturer
Middle of name

-lim

-cir

-tu

-Immune/inflammatory

-Cardiac disorder

-Tumor or neoplasm

End of name

-ximab

-zumab

-umab

Chimeric (murine variable region plus human Fc)

Humanized (murine complementarity determining region)

Human